-
Recent Posts
- Dementia-Friendly Communities Provision, Viewed as a Social Determinant of Health (JGCR / NHS England / WHO)
- International Perspectives on the Possible Impact of the COVID-19 Pandemic and Lockdown on Abuse of the Elderly (JGCR / American Journal of Geriatric Psychiatry / JAGS)
- Updates Relating to the Lancet Commission on Dementia Prevention, Intervention, and Care (Lancet / Alzheimer’s Research and Therapy / Alzheimer’s and Dementia)
- A Brief Review of How the COVID-19 Pandemic Relates to Elderly Care and Research (JGCR)
- Some Speculated / Potential Benefits of COVID-19 (JGCR / BBC Radio 4’s Rethink / BGS)
Archives
- September 2020
- August 2020
- June 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Disease-Modifying Treatments for Dementia
Cognitive Symptoms of Alzheimer’s Disease: Management and Prevention? (BMJ)
Summary A review investigates pharmacological treatments for cognitive symptoms in Alzheimer’s Disease at different phases in progression of the disease, in the context of the paucity of effective disease-modifying interventions. Discrepancies between different national and international guidelines, regarding the prescription … Continue reading →
Posted in Acute Hospitals, Community Care, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Models of Dementia Care, Non-Pharmacological Treatments, Person-Centred Care, Pharmacological Treatments, Quick Insights, Universal Interest
|
Tagged Acetylcholinesterase Inhibitors, Acetylcholinesterase Inhibitors (AChEIs), ADAS-Cog: Alzheimer’s Disease Assessment Scale - Cognitive Subscale, Alzheimer Disease Research Center: Keck School of Medicine at USC, Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog), American Geriatrics Society (AGS), Anti-Amyloid Immunotherapies, BMJ, BMJ Publishing Group Ltd, British Medical Journal (BMJ), Cambridge Institute of Public Health: University of Cambridge, Care of the Elderly Medicine Department: Royal Wolverhampton NHS Trust, ChEIs: Cholinesterase Inhibitors, Cholinergic Agents, Cholinergic Agonists, Cholinergic Enhancers, Cholinesterase Inhibitors, Choosing Wisely, Choosing Wisely Campaign, Cognitive Enhancing Medications, DAPA - Dementia and Physical Activity Trial, Deep Brain Stimulation (DBS), Department of Neurology: Keck School of Medicine at USC, Department of Public Health and Primary Care: University of Cambridge, Deprescribing, Disease-Modifying Therapies for Dementia, Disease-Modifying Treatments for Dementia, Disease-Modifying Treatments for Dementia (Hypothetical Scenarios), Disease-Modifying Trials in Mild-to-Moderate Dementia, Donepezil, Donepezil (Aricept), Donepezil and Memantine, Donepezil-Memantine Combination, Donepezil-Memantine: Monotherapy Versus Combination Therapy, Drug Efficacy, Drug Side-Effects, Drugs Alleged to Raise False Hopes (Speculative Construct), European Federation of Neurological Societies (EFNS), Fish Oil, Fortasyn Connect, Galantamine, Galantamine-Memantine Combination Versus Donepezil-Memantine Combination, Galantamine-Memantine Drug Combination, German Institute for Quality and Efficiency in Healthcare (IQWiG), Goal Attainment Scaling (GAS), Incidence and Prevalence of Alzheimer’s Disease, Keck School of Medicine, Keck School of Medicine at USC, Keck School of Medicine: University of Southern California, LEARNit Study (Midlife Exercise), Medical Foods, Memory Improvement Through Nicotine Dosing (MIND) Study, New Cross Hospital, New Cross Hospital: Royal Wolverhampton NHS Trust, Nicotine Patches, Nicotinic Agonists, NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association) Criteria for Alzheimer's Disease, NINCDS-ADRDA Criteria, NINCDS-ADRDA: National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer Disease and Related Disorders Association, Outcome Measures for Disease-Modifying Trials in Mild-to-Moderate Dementia, Physical Activity, Prescribing Guidelines: Acetyl Cholinesterase Inhibitors, Prescribing Review: Acetyl Cholinesterase Inhibitors, Razadyne, Reducing Waste in Dementia Care, Reducing Waste in the NHS, Rivastigmine, Royal Wolverhampton NHS Trust, Souvenaid Drink (Nutricia), Symptomatic Treatment: Inhibitors of Acetylcholinesterase, Tacrine, Treatment Algorithm for Alzheimer’s Disease, University of Cambridge, University of Southern California Keck School of Medicine, Vitamin E
|
Leave a comment
The State of Dementia Research Globally: World Alzheimer Report 2018 (Alzheimer’s Disease International)
Summary The World Alzheimer Report 2018, entitled “The state of the art of dementia research: New frontiers”, reviews developments in dementia research, without glossing-over the absence of significant disease-modifying pharmacological treatment breakthroughs for around 20 years. This report examines wide-ranging … Continue reading →
Posted in Acute Hospitals, Alzheimer’s Disease International (ADI), Charitable Bodies, Community Care, Diagnosis, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Mental Health, Models of Dementia Care, Person-Centred Care, Quick Insights, Standards, Statistics, UK, Universal Interest
|
Tagged ADI’s World Alzheimer Reports, Alireza Atri: Director of Banner Sun Health Research Institute, Alzheimer's Research, Alzheimer’s Disease International (ADI), Alzheimer’s Disease Research Unit: McGill Centre for Studies in Ageing (Canada), Alzheimer’s Prevention Initiative: Banner Health (USA), Alzheimer’s Prevention Initiative: Banner Sun Health Research Institute, Banner Sun Health Research Institute, Burden of Alzheimer’s Disease, Burden of Dementia (Statistics), Centre for Dementia Prevention: University of Edinburgh, Dementia as Cause of Death, Dementia Awareness, Dementia Awareness Raising, Dementia Collaborative Research Centre: University of New South Wales, Dementia Discovery Fund, Dementia Discovery Fund (DDF), Dementia Prevention, Dementia Research, Dementia Research Funding, Dementia Research Priorities, Dementia Risk Reduction, Dementia Risk Reduction and Prevention, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies for Dementia, Disease-Modifying Treatments for Dementia, Dr Christopher Chen: Director of Memory Ageing and Cognition Centre at National University Health System: Singapore, Dr Doug Brown: Chief Executive Officer of British Society for Immunology, Dr Doug Brown: Former Chief Policy and Research Officer at Alzheimer’s Society, Dr Jennifer Bute: Dementia Alliance International (DAI), Dr Kenji Toba: President of National Centre for Geriatrics and Gerontology (Obu), Dr Maria Carrillo: Chief Science Officer at Alzheimer’s Association US, Dr Miia Kivipelto: Karolinska Institute, Dr Miia Kivipelto: Karolinska University Hospital (Stockholm), Dr Rachelle Doody: Global Head of Neurodegeneration at Roche, Dr Serge Gauthier: Director of Alzheimer’s Disease Research Unit at McGill Centre for Studies in Ageing in Canada, Drug Trials Failure Rate, Epidemiology, Epidemiology and Statistics, Francesca Colombo: Organisation for Economic Co-operation and Development (OECD), Fundación para la Lucha contra las Enfermedades Neurológicas (FLENI), Glenn Rees: Chairman of Alzheimer’s Disease International, Glenn Rees: Former CEO of Alzheimer’s Australia, Global Burden of Dementia, Global Dementia Discovery Fund (2015), Identification and Intervention for Dementia in Elderly Africans (IDEA Group), Jeff Cummings: Director of Cleveland Clinic at Lou Ruvo Centre for Brain Health, Kate Bingham: SV Health Managers, King’s College London, Market Failure (Dementia Research and Drug Development), Martin Knapp: London School of Economics, Memory Ageing and Cognition Centre at National University Health System: Singapore, Memory Ageing and Cognition Centre: National University Health System (Singapore), National Centre for Geriatrics and Gerontology (Japan), Optima (University of Oxford’s Dementia Research Project), OPTIMA Cohort (Oxford Project to Investigate Memory and Ageing), Oxford Project to Investigate Memory and Ageing (OPTIMA Study), Paola Barbarino: Alzheimer’s Disease International, Prevention, Prevention Agenda, Prevention of Future Dementia Cases by Increasing Knowledge of Risk and Protective Factors, Professor Adesola Ogunniyi: University College Hospital (Ibadan), Professor Bart De Strooper: Director of the UK Dementia Research Institute (UK DRI), Professor Craig Ritchie: Chair of Psychiatry of Ageing at University of Edinburgh, Professor Craig Ritchie: Director at Centre for Dementia Prevention, Professor Gordon Wilcock: Co-founder of Alzheimer’s Society UK, Professor Gordon Wilcock: Emeritus Professor of Geratology at University of Oxford, Professor Henry Brodaty: Director of Dementia Collaborative Research Centre at University of New South Wales, Professor Martin Knapp: Director of the Personal Social Services Research Unit at the London School of Economics and Political Science (LSE), Professor Martin Prince: Assistant Principal for Global Health at King’s College London, Research Networks, Ricardo Allegri: Head of Cognitive Neurology Neuropsychology and Neuropsychiatry at Fundación para la Lucha contra las Enfermedades Neurológicas (FLENI), Risk and Protective Factors, State of the Art of Dementia Research: New Frontiers (World Alzheimer Report 2018), Supporting People Affected by Dementia, UK Dementia Research Institute, UK Dementia Research Institute (UK DRI), UK Dementia Research Institute at UCL, University College Hospital (Ibadan Nigeria), World Alzheimer Report, World Alzheimer Report 2018: State of the Art of Dementia Research, World Alzheimer Report: 2018, World Alzheimer’s Day 2018
|
Leave a comment
Young Blood Infusion Recapitulates Folklore: Vampire Therapy for Dementia? (Telegraph / CTAD / JPAD)
Summary A small trial to check the safety and tolerability of youthful blood infusions for the treatment or amelioration of Alzheimer’s Disease has detected early signs of improvement in activities of daily living. Randomly selected individuals from just 18 over-65 … Continue reading →
Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Models of Dementia Care, Non-Pharmacological Treatments, Quick Insights, Universal Interest
|
Tagged 10th Annual Clinical Trial on Alzheimer’s Disease (CTAD) Conference, Activities of Daily Living (ADLs), ADAS-Cog, Alkahest (San Carlos; USA), Alzheimer's Disease Assessment Scale (ADAS-Cog13), Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog), Alzheimer's Disease Co-operative Study - Activities of Daily Living Scale (ADCS-ADL), Alzheimer's Disease Co-operative Study-Activities of Daily Living Inventory (ADCS-ADL) Scale, Alzheimer’s Disease Cooperative Study - Activities of Daily Living (ADCS-ADL), Alzheimer’s Disease Cooperative Study / Activities of Daily Living (ADCS-ADL) Inventory, Alzheimer’s Therapeutic Research Institute: University of Southern California, Assessments of Functional Ability, Clinical Dementia Rating Scale, Clinical Dementia Rating Scale Sum of Boxes (CDR-SB), Department of Health Research and Policy: Stanford University, Department of Neurology and Neurological Sciences: Stanford University, Department of Neurosurgery: Stanford University, Department of Pediatrics: Stanford University, Disease Modification Trials, Disease Modifying Treatment by 2025 (Aim), Disease Modifying Versus Symptom Modifying Treatments (Widespread Mis-Classification in Drugs Development Pipeline), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Disease-Modifying Treatments for Dementia, Disease-Modifying Trials in Mild-to-Moderate Dementia, Folk Tales, Folklore, Functional Activities Questionnaire (FAQ), Geriatric Depression Scale, Geriatric Depression Scale (GDS Short Form), Infusion of Young Persons’ Plasma, Infusions of Plasma to Elderly People With Alzheimer’s Disease, Journal of Prevention of Alzheimer’s Disease (JPAD), Legends, Mini Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), Neuropsychiatric Inventory (NPI-Q), Outcome Measures for Disease-Modifying Trials in Mild-to-Moderate Dementia, PLASMA (Plasma for Alzheimer’s Symptom Amelioration) Trial, Plasma for Alzheimer’s Symptom Amelioration (PLASMA), Platelet-Rich Plasma Therapy (PRP), Repeated Infusions of Young Persons’ Plasma, Stanford University, The Journal of Prevention of Alzheimer's Disease, The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study (PLASMA), Trail Making Test Part A (TMTA), Trail Making Test Part B (TMTB, United States, University of Southern California, USA, USA Endocrinology, Vampire Therapy, Vampirism, Young Plasma
|
Leave a comment
NICE Participation in European ROADMAP Project: Faster Access to Alzheimer’s Disease Drugs? (NICE)
Summary NICE is participating in the ROADMAP initiative, which is working on a sustainable platform for “real world” evidence generation concerning Alzheimer’s Disease and (hopefully) faster development of disease-modifying drugs. “The IMI (Innovative Medicines Initiative) is Europe’s largest public-private partnership, … Continue reading →
Posted in Commissioning, For Researchers (mostly), In the News, International, National, Quick Insights, UK, Universal Interest
|
Tagged Academia-Industry Partnerships, Big Data, Big Data for Better Outcomes Programme (IMI), Big Data Funding and Research, Collaborative Projects, Cross-Sector Partnerships, Data Sharing, Dementia Research, Disease Modification, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Treatments for Dementia, Dr Matthew Norton: Alzheimer's Research UK, Electronic Health Records (EHRs), European ROADMAP Project, Global Leadership, Global Outlook, IMI (Innovative Medicines Initiative), IMI’s Big Data for Better Outcomes Programme, Innovative Medicines Initiative (IMI), International Collaborations, International Programmes, Leveraging Big Data, National Institute for Health and Care Excellence (NICE), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, NICE’s Science Policy and Research Programme, Pan-European Collaborations, Partnership, Partnership and Collaboration, Partnership Working, Prof Carole Longson: National Institute for Health and Care Excellence (NICE), Professor Carole Longson: Director of Centre for Health Technology Evaluation at NICE, Professor John Gallacher: University of Oxford, Promisary Science, Publicly-Funded UK Big Data Research, Research and Innovation, Resource and Incentives, ROADMAP Initiative
|
Leave a comment
